20 results on '"Ozaki, N."'
Search Results
2. 432. An association of a 5-HT5A receptor polymorphism, PRO15SER, to Japanese schizophrenia
- Author
-
Iwata, N., primary, Ozaki, N., additional, Inada, T., additional, and Goldman, D., additional
- Published
- 2000
- Full Text
- View/download PDF
3. Molecular genetics of impaired impulse control and early onset alcoholism
- Author
-
Goldman, D., primary, Nielsen, D., additional, Okada, M., additional, Adamson, M., additional, Lappalainen, J., additional, Malhotra, N., additional, Pesonen, U., additional, Koulu, M., additional, Eggert, M., additional, Virkkunen, M., additional, Ozaki, N., additional, and Linnoila, M., additional
- Published
- 1996
- Full Text
- View/download PDF
4. HTR2C Cys23Ser polymorphism in relation to CSF monoamine metabolite concentrations and DSM-III-R psychiatric diagnoses - Putative implications for psychiatry and psychopharmacology
- Author
-
Lappalainen, J., Long, J.C., Virkkunen, M., Ozaki, N., Goldman, D., and Linnoila, M.
- Published
- 1999
- Full Text
- View/download PDF
5. Two Naturally Occurring Amino Acid Substitutions of the 5-HT~2~A Receptor: Similar Prevalence in Patients with Seasonal Affective Disorder and Controls
- Author
-
Ozaki, N., Rosenthal, N. E., Pesonen, U., Lappalainen, J., Feldman-Naim, S., Schwartz, P. J., Turner, E. H., and Goldman, D.
- Published
- 1996
- Full Text
- View/download PDF
6. Platelet [^3H] Paroxetine Binding, 5-HT-Stimulated Ca^2^+ Response, and 5-HT Content in Winter Seasonal Affective Disorder
- Author
-
Ozaki, N., Rosenthal, N. E., Mazzola, P., and Chiueh, C. C.
- Published
- 1994
- Full Text
- View/download PDF
7. Cross-Disorder Analysis of Genic and Regulatory Copy Number Variations in Bipolar Disorder, Schizophrenia, and Autism Spectrum Disorder.
- Author
-
Kushima I, Nakatochi M, Aleksic B, Okada T, Kimura H, Kato H, Morikawa M, Inada T, Ishizuka K, Torii Y, Nakamura Y, Tanaka S, Imaeda M, Takahashi N, Yamamoto M, Iwamoto K, Nawa Y, Ogawa N, Iritani S, Hayashi Y, Lo T, Otgonbayar G, Furuta S, Iwata N, Ikeda M, Saito T, Ninomiya K, Okochi T, Hashimoto R, Yamamori H, Yasuda Y, Fujimoto M, Miura K, Itokawa M, Arai M, Miyashita M, Toriumi K, Ohi K, Shioiri T, Kitaichi K, Someya T, Watanabe Y, Egawa J, Takahashi T, Suzuki M, Sasaki T, Tochigi M, Nishimura F, Yamasue H, Kuwabara H, Wakuda T, Kato TA, Kanba S, Horikawa H, Usami M, Kodaira M, Watanabe K, Yoshikawa T, Toyota T, Yokoyama S, Munesue T, Kimura R, Funabiki Y, Kosaka H, Jung M, Kasai K, Ikegame T, Jinde S, Numata S, Kinoshita M, Kato T, Kakiuchi C, Yamakawa K, Suzuki T, Hashimoto N, Ishikawa S, Yamagata B, Nio S, Murai T, Son S, Kunii Y, Yabe H, Inagaki M, Goto YI, Okumura Y, Ito T, Arioka Y, Mori D, and Ozaki N
- Subjects
- Chromatin, DNA Copy Number Variations genetics, Genetic Predisposition to Disease, Genome-Wide Association Study methods, Humans, Autism Spectrum Disorder genetics, Bipolar Disorder genetics, Schizophrenia genetics
- Abstract
Background: We aimed to determine the similarities and differences in the roles of genic and regulatory copy number variations (CNVs) in bipolar disorder (BD), schizophrenia (SCZ), and autism spectrum disorder (ASD)., Methods: Based on high-resolution CNV data from 8708 Japanese samples, we performed to our knowledge the largest cross-disorder analysis of genic and regulatory CNVs in BD, SCZ, and ASD., Results: In genic CNVs, we found an increased burden of smaller (<100 kb) exonic deletions in BD, which contrasted with the highest burden of larger (>500 kb) exonic CNVs in SCZ/ASD. Pathogenic CNVs linked to neurodevelopmental disorders were significantly associated with the risk for each disorder, but BD and SCZ/ASD differed in terms of the effect size (smaller in BD) and subtype distribution of CNVs linked to neurodevelopmental disorders. We identified 3 synaptic genes (DLG2, PCDH15, and ASTN2) as risk factors for BD. Whereas gene set analysis showed that BD-associated pathways were restricted to chromatin biology, SCZ and ASD involved more extensive and similar pathways. Nevertheless, a correlation analysis of gene set results indicated weak but significant pathway similarities between BD and SCZ or ASD (r = 0.25-0.31). In SCZ and ASD, but not BD, CNVs were significantly enriched in enhancers and promoters in brain tissue., Conclusions: BD and SCZ/ASD differ in terms of CNV burden, characteristics of CNVs linked to neurodevelopmental disorders, and regulatory CNVs. On the other hand, they have shared molecular mechanisms, including chromatin biology. The BD risk genes identified here could provide insight into the pathogenesis of BD., (Copyright © 2022 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
8. Transethnic Replication Study to Assess the Association Between Clozapine-Induced Agranulocytosis/Granulocytopenia and Genes at 12p12.2 in a Japanese Population.
- Author
-
Saito T, Ikeda M, Hashimoto R, Iwata N, Yamamori H, Yasuda Y, Fujimoto M, Kondo K, Shimasaki A, Kawase K, Miyata M, Mushiroda T, Ozeki T, Kubo M, Fujita K, Kida N, Nakai M, Otsuru T, Fukuji Y, Murakami M, Mizuno K, Shiratsuchi T, Numata S, Ohmori T, Ueno SI, Yada Y, Tanaka S, Kishi Y, Takaki M, Mamoto A, Taniguchi N, Sawa Y, Watanabe H, Noda T, Amano Y, Kimura T, Fukao T, Suwa T, Murai T, Kubota M, Ueda K, Tabuse H, Kanahara N, Kawai N, Nemoto K, Makinodan M, Nishihata Y, Hashimoto N, Kusumi I, Fujii Y, Miyata R, Hirakawa K, and Ozaki N
- Subjects
- Antipsychotic Agents adverse effects, Case-Control Studies, Humans, Japan, Polymorphism, Single Nucleotide genetics, Agranulocytosis chemically induced, Agranulocytosis genetics, Asian People genetics, Chromosomes, Human, Pair 12 genetics, Clozapine adverse effects, Genetic Predisposition to Disease genetics
- Published
- 2017
- Full Text
- View/download PDF
9. A population-specific uncommon variant in GRIN3A associated with schizophrenia.
- Author
-
Takata A, Iwayama Y, Fukuo Y, Ikeda M, Okochi T, Maekawa M, Toyota T, Yamada K, Hattori E, Ohnishi T, Toyoshima M, Ujike H, Inada T, Kunugi H, Ozaki N, Nanko S, Nakamura K, Mori N, Kanba S, Iwata N, Kato T, and Yoshikawa T
- Subjects
- Asian People psychology, Bipolar Disorder genetics, Case-Control Studies, Female, Genetic Association Studies, Genotype, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide genetics, Asian People genetics, Genetic Predisposition to Disease genetics, Receptors, N-Methyl-D-Aspartate genetics, Schizophrenia genetics
- Abstract
Background: Genome-wide association studies have successfully identified several common variants showing robust association with schizophrenia. However, individually, these variants only produce a weak effect. To identify genetic variants with larger effect sizes, increasing attention is now being paid to uncommon and rare variants., Methods: From the 1000 Genomes Project data, we selected 47 candidate single nucleotide variants (SNVs), which were: 1) uncommon (minor allele frequency < 5%); 2) Asian-specific; 3) missense, nonsense, or splice site variants predicted to be damaging; and 4) located in candidate genes for schizophrenia and bipolar disorder. We examined their association with schizophrenia, using a Japanese case-control cohort (2012 cases and 2781 control subjects). Additional meta-analysis was performed using genotyping data from independent Han-Chinese case-control (333 cases and 369 control subjects) and family samples (9 trios and 284 quads)., Results: We identified disease association of a missense variant in GRIN3A (p.R480G, rs149729514, p = .00042, odds ratio [OR] = 1.58), encoding a subunit of the N-methyl-D-aspartate type glutamate receptor, with study-wide significance (threshold p = .0012). This association was supported by meta-analysis (combined p = 3.3 × 10(-5), OR = 1.61). Nominally significant association was observed in missense variants from FAAH, DNMT1, MYO18B, and CFB, with ORs of risk alleles ranging from 1.41 to 2.35., Conclusions: The identified SNVs, particularly the GRIN3A R480G variant, are good candidates for further replication studies and functional evaluation. The results of this study indicate that association analyses focusing on uncommon and rare SNVs are a promising way to discover risk variants with larger effects., (Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
10. Loss of function studies in mice and genetic association link receptor protein tyrosine phosphatase α to schizophrenia.
- Author
-
Takahashi N, Nielsen KS, Aleksic B, Petersen S, Ikeda M, Kushima I, Vacaresse N, Ujike H, Iwata N, Dubreuil V, Mirza N, Sakurai T, Ozaki N, Buxbaum JD, and Sap J
- Subjects
- Animals, Behavior, Animal physiology, Disease Models, Animal, Gene Expression, Genetic Association Studies methods, Humans, Mice, Mice, Inbred C57BL, Mice, Knockout, Myelin Sheath genetics, Polymorphism, Genetic, Prefrontal Cortex metabolism, Receptor-Like Protein Tyrosine Phosphatases, Class 4 biosynthesis, Receptor-Like Protein Tyrosine Phosphatases, Class 4 genetics, Genetic Predisposition to Disease genetics, Receptor-Like Protein Tyrosine Phosphatases, Class 4 physiology, Schizophrenia genetics, Schizophrenia physiopathology, Schizophrenic Psychology
- Abstract
Background: Solid evidence links schizophrenia (SZ) susceptibility to neurodevelopmental processes involving tyrosine phosphorylation-mediated signaling. Mouse studies implicate the Ptpra gene, encoding protein tyrosine phosphatase RPTPα, in the control of radial neuronal migration, cortical cytoarchitecture, and oligodendrocyte differentiation. The human gene encoding RPTPα, PTPRA, maps to a chromosomal region (20p13) associated with susceptibility to psychotic illness., Methods: We characterized neurobehavioral parameters, as well as gene expression in the central nervous system, of mice with a null mutation in the Ptpra gene. We searched for genetic association between polymorphisms in PTPRA and schizophrenia risk (two independent cohorts, 1420 cases and 1377 controls), and we monitored PTPRA expression in prefrontal dorsolateral cortex of SZ patients (35 cases, 2 control groups of 35 cases)., Results: We found that Ptpra⁻/⁻ mice reproduce neurobehavioral endophenotypes of human SZ: sensitization to methamphetamine-induced hyperactivity, defective sensorimotor gating, and defective habituation to a startle response. Ptpra loss of function also leads to reduced expression of multiple myelination genes, mimicking the hypomyelination-associated changes in gene expression observed in postmortem patient brains. We further report that a polymorphism at the PTPRA locus is genetically associated with SZ, and that PTPRA mRNA levels are reduced in postmortem dorsolateral prefrontal cortex of subjects with SZ., Conclusions: The implication of this well-studied signaling protein in SZ risk and endophenotype manifestation provides novel entry points into the etiopathology of this disease., (Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
11. Genome-wide association study of schizophrenia in a Japanese population.
- Author
-
Ikeda M, Aleksic B, Kinoshita Y, Okochi T, Kawashima K, Kushima I, Ito Y, Nakamura Y, Kishi T, Okumura T, Fukuo Y, Williams HJ, Hamshere ML, Ivanov D, Inada T, Suzuki M, Hashimoto R, Ujike H, Takeda M, Craddock N, Kaibuchi K, Owen MJ, Ozaki N, O'Donovan MC, and Iwata N
- Subjects
- Adult, Alleles, Asian People, Female, Follow-Up Studies, Gene Frequency, Genetic Markers, Genetic Predisposition to Disease, Genotype, Haplotypes, Humans, Japan epidemiology, Male, Middle Aged, Multifactorial Inheritance, Polymorphism, Single Nucleotide, Quality Control, Reverse Transcriptase Polymerase Chain Reaction, United Kingdom epidemiology, Genome-Wide Association Study, Schizophrenia epidemiology, Schizophrenia genetics
- Abstract
Background: Genome-wide association studies have detected a small number of weak but strongly supported schizophrenia risk alleles. Moreover, a substantial polygenic component to the disorder consisting of a large number of such alleles has been reported by the International Schizophrenia Consortium., Method: We report a Japanese genome-wide association study of schizophrenia comprising 575 cases and 564 controls. We attempted to replicate 97 markers, representing a nonredundant panel of markers derived mainly from the top 150 findings, in up to three data sets totaling 1990 cases and 5389 controls. We then attempted to replicate the observation of a polygenic component to the disorder in the Japanese and to determine whether this overlaps that seen in UK populations., Results: Single-locus analysis did not reveal genome-wide support for any locus in the genome-wide association study sample (best p = 6.2 × 10(-6)) or in the complete data set in which the best supported locus was SULT6B1 (rs11895771: p = 3.7 × 10(-5) in the meta-analysis). Of loci previously supported by genome-wide association studies, we obtained in the Japanese support for NOTCH4 (rs2071287: p(meta) = 5.1 × 10(-5)). Using the approach reported by the International Schizophrenia Consortium, we replicated the observation of a polygenic component to schizophrenia within the Japanese population (p = .005). Our trans Japan-UK analysis of schizophrenia also revealed a significant correlation (best p = 7.0 × 10(-5)) in the polygenic component across populations., Conclusions: These results indicate a shared polygenic risk of schizophrenia between Japanese and Caucasian samples, although we did not detect unequivocal evidence for a novel susceptibility gene for schizophrenia., (Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
12. Brain cannabinoid CB2 receptor in schizophrenia.
- Author
-
Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y, Morikawa M, Inada T, Watanabe Y, Takahashi M, Someya T, Ujike H, Iwata N, Ozaki N, Onaivi ES, Kunugi H, Sasaki T, Itokawa M, Arai M, Niizato K, Iritani S, Naka I, Ohashi J, Kakita A, Takahashi H, Nawa H, and Arinami T
- Subjects
- Animals, CHO Cells, Case-Control Studies, Cricetinae, Cricetulus, Cyclic AMP metabolism, Gene Expression Regulation, Genetic Predisposition to Disease, Humans, Indoles pharmacology, Mice, Mice, Inbred C57BL, Motor Activity drug effects, Polymorphism, Single Nucleotide, Receptor, Cannabinoid, CB2 antagonists & inhibitors, Reflex, Startle drug effects, Brain metabolism, Receptor, Cannabinoid, CB2 genetics, Receptor, Cannabinoid, CB2 metabolism, Schizophrenia genetics, Schizophrenia metabolism
- Abstract
Background: Neural endocannabinoid function appears to be involved in schizophrenia. Two endocannabinoid receptors, CB1 and CB2, are found in the brain and elsewhere in the body. We investigated roles of CB2 in schizophrenia., Materials and Methods: An association study was performed between tag single nucleotide polymorphisms (SNPs) in the CNR2 gene encoding the CB2 receptor and schizophrenia in two independent case-control populations. Allelic differences of associated SNPs were analyzed in human postmortem brain tissues and in cultured cells. Prepulse inhibition and locomotor activity in C57BL/6JJmsSlc mice with CB2 receptor antagonist AM630 administration was examined., Results: The analysis in the first population revealed nominally significant associations between schizophrenia and two SNPs, and the associations were replicated in the second population. The R63 allele of rs2501432 (R63Q) (p = .001), the C allele of rs12744386 (p = .005) and the haplotype of the R63-C allele (p = 5 x 10(-6)) were significantly increased among 1920 patients with schizophrenia compared with 1920 control subjects in the combined population. A significantly lower response to CB2 ligands in cultured CHO cells transfected with the R63 allele compared with those with Q63, and significantly lower CB2 receptor mRNA and protein levels found in human brain with the CC and CT genotypes of rs12744386 compared with TT genotype were observed. AM630 exacerbated MK-801- or methamphetamine-induced disturbance of prepulse inhibition and hyperactivity in C57BL/6JJmsSlc mice., Conclusions: These findings indicate an increased risk of schizophrenia for people with low CB2 receptor function., (Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
13. Copy number variation in schizophrenia in the Japanese population.
- Author
-
Ikeda M, Aleksic B, Kirov G, Kinoshita Y, Yamanouchi Y, Kitajima T, Kawashima K, Okochi T, Kishi T, Zaharieva I, Owen MJ, O'Donovan MC, Ozaki N, and Iwata N
- Subjects
- Adult, Asian People genetics, Case-Control Studies, Female, Gene Expression Profiling, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotype, Humans, Japan, Male, Middle Aged, Oligonucleotide Array Sequence Analysis methods, DNA Copy Number Variations genetics, Genetic Variation, Schizophrenia genetics
- Abstract
Background: Copy number variants (CNVs) have been shown to increase the risk to develop schizophrenia. The best supported findings are at 1q21.1, 15q11.2, 15q13.3, and 22q11.2 and deletions at the gene neurexin 1 (NRXN1)., Methods: In this study, we used Affymetrix 5.0 arrays to investigate the role of rare CNVs in 575 patients with schizophrenia and 564 control subjects from Japan., Results: There was a nonsignificant trend for excess of rare CNVs in schizophrenia (p = .087); however, we did not confirm the previously implicated association for very large CNVs (>500 kilobase [kb]) in this population. We provide support for three previous findings in schizophrenia, as we identified one deletion in a case at 1q21.1, one deletion within NRXN1, and four duplications in cases and one in a control subject at 16p13.1, a locus first implicated in autism and later in schizophrenia., Conclusions: In this population, we support some of the previous findings in schizophrenia but could not find an increased burden of very large (>500 kb) CNVs, which was proposed recently. However, we provide support for the role of CNVs at 16p13.1, 1q21.1, and NRXN1., (Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
14. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches.
- Author
-
Ikeda M, Tomita Y, Mouri A, Koga M, Okochi T, Yoshimura R, Yamanouchi Y, Kinoshita Y, Hashimoto R, Williams HJ, Takeda M, Nakamura J, Nabeshima T, Owen MJ, O'Donovan MC, Honda H, Arinami T, Ozaki N, and Iwata N
- Subjects
- Animals, Case-Control Studies, Databases, Genetic statistics & numerical data, Gene Frequency, Genome-Wide Association Study, Genotype, Humans, Mice, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Prefrontal Cortex drug effects, Prefrontal Cortex metabolism, Prefrontal Cortex pathology, Psychiatric Status Rating Scales, Antipsychotic Agents therapeutic use, Genetic Predisposition to Disease, Pharmacogenetics, Risperidone therapeutic use, Schizophrenia drug therapy, Schizophrenia genetics
- Abstract
Background: Pharmacogenomic approaches based on genomewide sets of single nucleotide polymorphisms (SNPs) are now feasible and offer the potential to uncover variants that influence drug response., Methods: To detect potential predictor gene variants for risperidone response in schizophrenic subjects, we performed a convergent analysis based on 1) a genomewide (100K SNP) SNP pharmacogenetic study of risperidone response and 2) a global transcriptome study of genes with mRNA levels influenced by risperidone exposure in mouse prefrontal cortex., Results: Fourteen genes were highlighted as of potential relevance to risperidone activity in both studies: ATP2B2, HS3ST2, UNC5C, BAG3, PDE7B, PAICS, PTGFRN, NR3C2, ZBTB20, ST6GAL2, PIP5K1B, EPHA6, KCNH5, and AJAP1. The SNPs related to these genes that were associated in the pharmacogenetic study were further assessed for evidence for association with schizophrenia in up to three case-control series comprising 1564 cases and 3862 controls in total (Japanese [JPN] 1st and 2nd samples and UK sample). Of 14 SNPs tested, one (rs9389370) in PDE7B showed significant evidence for association with schizophrenia in a discovery sample (p(allele) = .026 in JPN_1st, two-tailed). This finding replicated in a joint analysis of two independent case-control samples (p(JPN_2nd+UK) = .008, one-tailed, uncorrected) and in all combined data sets (p(all) = .0014, two-tailed, uncorrected and p(all) = .018, two-tailed, Bonferroni correction)., Conclusions: We identified novel candidate genes for treatment response to risperidone and provide evidence that one of these additionally may confer susceptibility to schizophrenia. Specifically, PDE7B is an attractive candidate gene, although evidence from integrated methodology, including pharmacogenomics, pharmacotranscriptomic, and case-control association approaches., (Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
15. The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis.
- Author
-
Kishimoto M, Ujike H, Motohashi Y, Tanaka Y, Okahisa Y, Kotaka T, Harano M, Inada T, Yamada M, Komiyama T, Hori T, Sekine Y, Iwata N, Sora I, Iyo M, Ozaki N, and Kuroda S
- Subjects
- Adult, Case-Control Studies, DNA Mutational Analysis, Dysbindin, Dystrophin-Associated Proteins, Female, Humans, Male, Middle Aged, Statistics, Nonparametric, Carrier Proteins genetics, Genetic Predisposition to Disease, Methamphetamine adverse effects, Polymorphism, Single Nucleotide genetics, Psychoses, Substance-Induced genetics
- Abstract
Background: The dysbindin (DTNBP1 [dystrobrevin-binding protein 1]) gene has repeatedly been shown to be associated with schizophrenia across diverse populations. One study also showed that risk haplotypes were shared with a bipolar disorder subgroup with psychotic episodes, but not with all cases. DTNBP1 may confer susceptibility to psychotic symptoms in various psychiatric disorders besides schizophrenia., Methods: Methamphetamine psychosis, the psychotic symptoms of which are close to those observed in schizophrenia, was investigated through a case (n = 197)-control (n = 243) association analyses of DTNBP1., Results: DTNBP1 showed significant associations with methamphetamine psychosis at polymorphisms of P1635 (rs3213207, p = .00003) and SNPA (rs2619538, p = .049) and the three-locus haplotype of P1655 (rs2619539)-P1635-SNPA (permutation p = .0005). The C-A-A haplotype, which was identical to the protective haplotype previously reported for schizophrenia and psychotic bipolar disorders, was a protective factor (p = .0013, odds ratio [OR] = .62, 95% confidence interval [CI] .51-.77) for methamphetamine psychosis. The C-G-T haplotype was a risk for methamphetamine psychosis (p = .0012, OR = 14.9, 95% CI 3.5-64.2)., Conclusions: Our genetic evidence suggests that DTNBP1 is involved in psychotic liability not only for schizophrenia but also for other psychotic disorders, including substance-induced psychosis.
- Published
- 2008
- Full Text
- View/download PDF
16. Association analysis of chromosome 5 GABAA receptor cluster in Japanese schizophrenia patients.
- Author
-
Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y, Inada T, Ujike H, and Ozaki N
- Subjects
- Adult, Cluster Analysis, Female, Gene Frequency, Genotype, Humans, Japan epidemiology, Linkage Disequilibrium, Male, Middle Aged, Phenotype, Polymorphism, Single Nucleotide genetics, Protein Subunits genetics, Chromosomes, Human, Pair 5, Genetic Predisposition to Disease, Receptors, GABA-A genetics, Schizophrenia genetics
- Abstract
Background: Several investigations suggest that abnormalities in gamma-amino butyric acid (GABA) neurotransmission systems may be related to the pathophysiology of schizophrenia. A GABA(A) receptor gene cluster on 5q31-35 (beta2 [GABRB2], alpha6 [GABRA6], alpha1 [GABRA1], and gamma2 [GABRG2] subunit genes) is one of the most attractive candidate regions for schizophrenia susceptibility., Methods: We performed 1) systematic polymorphism search of GABRB2, GABRA6, and GABRA1, in addition to our colleague's study of GABRG2; 2) evaluation of linkage disequilibrium (LD) within this cluster with 35 single nucleotide polymorphisms (SNPs); 3) "selection of haplotype-tagging (ht) SNPs"; and 4) two-stage association analysis that comprised first-set screening analysis of all htSNPs (288 Japanese schizophrenia patients and 288 control subjects) and second-set replication analysis of the positive htSNPs (901 schizophrenic patients and 806 control subjects)., Results: In the first-set scan, we found a significant association of two htSNPs in GABRA1, but no association of GABRB2, GABRA6, and GABRG2. In the following second-set analysis, however, we could not confirm these significant associations., Conclusions: These results indicate that this gene cluster may not play a major role in Japanese schizophrenia. They also raised an alert with regard to preliminary genetic association analysis using a small sample size.
- Published
- 2005
- Full Text
- View/download PDF
17. Association of AKT1 with schizophrenia confirmed in a Japanese population.
- Author
-
Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y, Inada T, and Ozaki N
- Subjects
- Alleles, Case-Control Studies, Female, Genotype, Humans, Japan epidemiology, Linkage Disequilibrium, Male, Middle Aged, Polymorphism, Single Nucleotide genetics, Proto-Oncogene Proteins c-akt, Schizophrenia epidemiology, Asian People genetics, Genetic Predisposition to Disease genetics, Protein Serine-Threonine Kinases genetics, Proto-Oncogene Proteins genetics, Schizophrenia genetics
- Abstract
Background: Abnormality of the V-akt murine thymoma viral oncogene homologue 1 (AKT1) may be a predisposing factor in schizophrenia. Recent evidence supporting this hypothesis showed decreased AKT1 protein levels in patients with schizophrenia and significant association of AKT1 haplotypes according to the transmission disequilibrium test., Methods: We provide the first replication of this evidence using a relatively large case-control sample (507 Japanese schizophrenia and 437 control subjects). We genotyped five single nucleotide polymorphisms (SNPs) from the original study and one additional SNP., Results: We found a positive association with an SNP (SNP5) different from the original study's findings (SNP3) and also significance in the haplotypes constructed from the combination of SNP5. Linkage disequilibrium around SNP5 was complex and may produce this positive association., Conclusions: Our study provides support for the theory that AKT1 is a susceptibility gene for Japanese schizophrenia. Fine linkage disequilibrium mapping is required for a conclusive result.
- Published
- 2004
- Full Text
- View/download PDF
18. No association between the Val66Met polymorphism of the brain-derived neurotrophic factor gene and bipolar disorder in a Japanese population: a multicenter study.
- Author
-
Kunugi H, Iijima Y, Tatsumi M, Yoshida M, Hashimoto R, Kato T, Sakamoto K, Fukunaga T, Inada T, Suzuki T, Iwata N, Ozaki N, Yamada K, and Yoshikawa T
- Subjects
- Adult, Analysis of Variance, Bipolar Disorder epidemiology, Chi-Square Distribution, Female, Gene Frequency, Genotype, Humans, Japan epidemiology, Male, Middle Aged, RNA, Messenger biosynthesis, Reverse Transcriptase Polymerase Chain Reaction methods, Bipolar Disorder genetics, Brain-Derived Neurotrophic Factor genetics, Methionine genetics, Polymorphism, Genetic genetics, Valine genetics
- Abstract
Background: Two previous studies reported a significant association between a missense polymorphism (Val66Met) in the brain-derived neurotrophic factor (BDNF) gene and bipolar disorder; however, contradictory negative results have also been reported, necessitating further investigation., Methods: We organized a multicenter study of a relatively large sample of 519 patients with bipolar disorder (according to DSM-IV criteria) and 588 control subjects matched for gender, age, and ethnicity (Japanese). Genotyping was done by polymerase chain reaction-based restriction fragment length polymorphism or direct sequencing., Results: The genotype distributions and allele frequencies were similar among the patients and control subjects. Even if the possible relationships of the polymorphism with several clinical variables (i.e., bipolar I or II, presence of psychotic features, family history, and age of onset) were examined, no variable was related to the polymorphism., Conclusions: The Val66Met polymorphism of the BDNF gene is unrelated to the development or clinical features of bipolar disorder, at least in a Japanese population.
- Published
- 2004
- Full Text
- View/download PDF
19. Platelet [3H]paroxetine binding, 5-HT-stimulated Ca2+ response, and 5-HT content in winter seasonal affective disorder.
- Author
-
Ozaki N, Rosenthal NE, Mazzola P, Chiueh CC, Hardin T, Garcia-Borreguero D, Schwartz PJ, Turner E, Oren DA, and Murphy DL
- Subjects
- Adult, Binding Sites, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Seasonal Affective Disorder psychology, Blood Platelets metabolism, Calcium metabolism, Paroxetine metabolism, Seasonal Affective Disorder metabolism, Serotonin metabolism
- Abstract
The present study was designed to evaluate cellular serotonergic functions in winter seasonal affective disorder (SAD) using serotonin (5-HT)-stimulated Ca2+ response as an integrated measure of 5-HT2 receptor function in platelets, [3H]paroxetine binding to characterize the platelet 5-HT transporter and 5-HT content as an index of the platelet storage capacity for this neurotransmitter amine. Purified density-dependent subpopulations of platelets in untreated and light-treated SAD patients and matched controls were investigated in order to control for possible variations in platelet turnover. We found no differences between SAD patients and controls on any of the measures, nor between light therapy conditions in SAD patients, although we found a higher Bmax of [3H]paroxetine binding and 5-HT content in heavy platelets compared to light platelets. Although the validity of platelet serotonergic measures as a model for brain serotonergic systems still remains to be elucidated, we found no evidence of platelet serotonergic abnormalities in our sample of SAD patients.
- Published
- 1994
- Full Text
- View/download PDF
20. The plasma tetrahydrobiopterin levels in patients with affective disorders.
- Author
-
Hashimoto R, Ozaki N, Ohta T, Kasahara Y, Kaneda N, and Nagatsu T
- Subjects
- Adult, Biopterins blood, Bipolar Disorder psychology, Depressive Disorder psychology, Female, Humans, Male, Middle Aged, Personality Inventory, Biopterins analogs & derivatives, Bipolar Disorder blood, Depressive Disorder blood
- Published
- 1990
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.